Annals of Oncology 9:1351-1353, 1998
© 1998 European Society for Medical Oncology
brief-report |
Therapy with gemcitabine in pretreated peripheral T-cell lymphoma patients
Institute of Hematology and Medical Oncology ‘Seràgnoli’, and 2nd Service of Pathologic Anatomy, University of Bologna Bologna, Italy
Correspondence to: Pier Luigi Zinzani, MD Istituto di Ematologia ed Oncologia Medica ‘L. e A. Seragnoli’ Policlinico S.Orsola Via Massarenti 9 40138 Bologna Italy
Background Gemcitabine is a novel nucleoside analogue which has shown promising results in most solid tumors; like the arabinosylcytosine analogue, gemcitabine may be an active drug in lymphoproliferative malignancies. We tested it in pretreated peripheral T-cell lymphoma patients with isolated skin involvement.
Patients and methods: We performed a phase II study with the drug in 13 pretreated patients with peripheral T-cell lymphoma, five of whom had advanced-stage mycosis fungoides (MF), and eight peripheral T-cell lymphoma unspecified (PTCLU). Patients were treated on days 1, 8, and 15 of a 28-day schedule at the dosage of 1200 mg/m2 for a total of three courses.
Results: Of the 13 patients, one achieved complete response (CR) and eight achieved partial responses (PR); the remaining four showed no benefit from the treatment. Among the res-ponders, one CR and four PR were documented in the PTCLU patients and four PR in MF patients. Treatment was well tolerated; hematologic toxicity was mild and no nausea/vomiting or organ toxicity was recorded.
Conclusions: In view of its significant activity and its modest toxicity profile, the role of gemcitabine deserves further evaluation in the management of pretreated patients with peripheral T-cell lymphoma.
gemcitabine, mycosis fungoides, peripheral T-cell lymphoma, skin involvement
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  F. Ravandi, A. Aribi, S. O'Brien, S. Faderl, D. Jones, A. Ferrajoli, X. Huang, S. York, S. Pierce, W. Wierda, et al. Phase II Study of Alemtuzumab in Combination With Pentostatin in Patients With T-Cell Neoplasms J. Clin. Oncol., November 10, 2009; 27(32): 5425 - 5430. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. L. Zinzani, F. Venturini, V. Stefoni, M. Fina, C. Pellegrini, E. Derenzini, L. Gandolfi, A. Broccoli, L. Argnani, F. Quirini, et al. Gemcitabine as single agent in pretreated T-cell lymphoma patients: evaluation of the long-term outcome Ann. Onc., November 3, 2009; (2009) mdp508v1. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. Pro Novel Agents in Peripheral T-cell Lymphomas ASCO Educational Book, January 1, 2009; 2009(1): 486 - 489. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
International T-Cell Lymphoma Project International Peripheral T-Cell and Natural Killer/T-Cell Lymphoma Study: Pathology Findings and Clinical Outcomes J. Clin. Oncol., September 1, 2008; 26(25): 4124 - 4130. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. M. Horwitz Novel Therapies and Role of Transplant in the Treatment of Peripheral T-Cell Lymphomas Hematology, January 1, 2008; 2008(1): 289 - 296. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. L. Zinzani, G. Musuraca, M. Tani, V. Stefoni, E. Marchi, M. Fina, C. Pellegrini, L. Alinari, E. Derenzini, A. de Vivo, et al. Phase II Trial of Proteasome Inhibitor Bortezomib in Patients With Relapsed or Refractory Cutaneous T-Cell Lymphoma J. Clin. Oncol., September 20, 2007; 25(27): 4293 - 4297. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F Morschhauser, S Depil, E Jourdan, M Wetterwald, R Bouabdallah, G Marit, P Solal-Celigny, C Sebban, B Coiffier, N Chouaki, et al. Phase II study of gemcitabine-dexamethasone with or without cisplatin in relapsed or refractory mantle cell lymphoma Ann. Onc., February 1, 2007; 18(2): 370 - 375. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. A. Rizvi, A. M. Evens, M. S. Tallman, B. P. Nelson, and S. T. Rosen T-cell non-Hodgkin lymphoma Blood, February 15, 2006; 107(4): 1255 - 1264. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. J. Savage, M. Chhanabhai, R. D. Gascoyne, and J. M. Connors Characterization of peripheral T-cell lymphomas in a single North American institution by the WHO classification Ann. Onc., October 1, 2004; 15(10): 1467 - 1475. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. Weidmann, M. Gramatzki, M. Wilhelm, and P. S. Mitrou Diagnosis and actual therapy strategies in peripheral T-cell lymphomas: summary of an international meeting Ann. Onc., March 1, 2004; 15(3): 369 - 374. [Full Text] [PDF]
|
|
|
|
|
|
P. L. Zinzani, G. Baliva, M. Magagnoli, M. Bendandi, G. Modugno, F. Gherlinzoni, G. F. Orcioni, S. Ascani, R. Simoni, S. A. Pileri, et al. Gemcitabine Treatment in Pretreated Cutaneous T-Cell Lymphoma: Experience in 44 Patients J. Clin. Oncol., July 1, 2000; 18(13): 2603 - 2606. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Santoro, H. Bredenfeld, L. Devizzi, H. Tesch, V. Bonfante, S. Viviani, F. Fiedler, H. S. Parra, C. Benoehr, M. Pacini, et al. Gemcitabine in the Treatment of Refractory Hodgkin's Disease: Results of a Multicenter Phase II Study J. Clin. Oncol., July 1, 2000; 18(13): 2615 - 2619. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L.-Y. Yang, L. Li, H. Jiang, Y. Shen, and W. Plunkett Expression of ERCC1 Antisense RNA Abrogates Gemcitabine-mediated Cytotoxic Synergism with Cisplatin in Human Colon Tumor Cells Defective in Mismatch Repair but Proficient in Nucleotide Excision Repair Clin. Cancer Res., March 1, 2000; 6(3): 773 - 781. [Abstract] [Full Text]
|
|